NASDAQ : LSTA
Lisata Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.02 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.19M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.37M |
| Enterprise Value | -1.07M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.01M |
| Shares Outstanding | 9.01M |
| Shares Change (YoY) | +5.10% |
| Shares Change (QoQ) | +1.11% |
| Owned by Insiders (%) | 23.29% |
| Owned by Institutions (%) | 13.39% |
| Float | 6.91M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 91.91 |
| Forward PS | n/a |
| PB Ratio | 1.13 |
| P/TBV Ratio | 1.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.69 |
| Quick Ratio | 3.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -101.66% |
| Return on Assets (ROA) | -56.74% |
| Return on Invested Capital (ROIC) | -71.26% |
| Return on Capital Employed (ROCE) | -204.30% |
| Weighted Average Cost of Capital (WACC) | 9.45% |
| Revenue Per Employee | $4,762 |
| Profits Per Employee | -$696,238 |
| Employee Count | 21 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -387,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.94 |
| 52-Week Price Change | -63.44% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 2.99 |
| Relative Strength Index (RSI) | 38.79 |
| Average Volume (20 Days) | 110,312 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 28,797 |
| Short Previous Month | 39,407 |
| Short % of Shares Out | 0.32% |
| Short % of Float | 0.42% |
| Short Ratio (days to cover) | 0.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 100,000 |
| Gross Profit | 100,000 |
| Operating Income | -16.43M |
| Pretax Income | -15.01M |
| Net Income | -14.62M |
| EBITDA | -16.36M |
| EBIT | -16.43M |
| Loss Per Share | -$1.64 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 10.44M |
| Total Debt | n/a |
| Net Cash | 10.44M |
| Net Cash Per Share | $1.16 |
| Equity (Book Value) | 7.99M |
| Book Value Per Share | 0.90 |
| Working Capital | 8.03M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.32M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 64,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.32M |
| FCF Per Share | -$1.37 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -16,426.00% |
| Pretax Margin | -15,008.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.10% |
| Shareholder Yield | -5.10% |
| Earnings Yield | -157.73% |
| FCF Yield | -134.07% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 248.57% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 15, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -71.25 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |